2025-07-24 - Analysis Report
Okay, here's an analysis of Eli Lilly and Co (LLY) based on the information you provided, formatted for a report.

## Eli Lilly and Co (LLY) Stock Analysis

**Ticker:** LLY
**Company:** Eli Lilly and Co
**Description:** Eli Lilly and Co. is a global pharmaceutical company that discovers, develops, manufactures, and markets pharmaceutical products.

### 1. Performance Relative to S&P 500 (VOO)

*   **LLY Cumulative Return:** 243.78%
*   **VOO Cumulative Return:** 97.07%
*   **Absolute Spread (LLY - VOO):** 146.7
*   **Spread Range (Min: -27.3, Max: 311.6):** The spread between LLY's return and the S&P 500 ranges from -27.3 to 311.6.
*   **Relative Spread Position:** 51.3. This indicates that LLY's current outperformance relative to the S&P 500 is positioned in the 51.3th percentile of its historical range.

**Analysis:** LLY has significantly outperformed the S&P 500 over the analyzed period. The current spread is quite high, suggesting substantial relative strength, but not in the higher percentile.

**Alpha/Beta Analysis:**

| Year       | CAGR   | MDD    | Alpha  | Beta   | Cap(B) |
|------------|--------|--------|--------|--------|--------|
| 2015-2017  | 10.0%  | 56.3%  | -19.0% | 0.0    | 77.7   |
| 2016-2018  | 39.0%  | 58.6%  | 21.0%  | -0.1   | 106.5  |
| 2017-2019  | 50.0%  | 58.6%  | 20.0%  | 0.3    | 121.0  |
| 2018-2020  | 52.0%  | 58.6%  | 33.0%  | 0.1    | 155.4  |
| 2019-2021  | 106.0% | 60.6%  | 57.0%  | 0.2    | 254.2  |
| 2020-2022  | 98.0%  | 64.8%  | 96.0%  | 0.2    | 336.7  |
| 2021-2023  | 133.0% | 64.8%  | 115.0% | 0.3    | 536.5  |
| 2022-2024  | 150.0% | 72.2%  | 124.0% | 0.2    | 710.5  |
| 2023-2025  | 97.0%  | 76.8%  | 48.0%  | 0.2    | 714.6  |

**Analysis:**

*   **CAGR:**  Compound Annual Growth Rate shows strong growth trends, particularly in recent years.
*   **MDD:** Maximum Drawdown is relatively high, indicating significant volatility.
*   **Alpha:**  Consistently positive and increasing, suggesting LLY is generating returns independent of the market.
*   **Beta:**  Low Beta values indicate that LLY is less sensitive to market movements than the S&P 500.
*   **Cap(B):** Market capitalization has increased significantly, reflecting strong growth.

### 2. Recent Price Action

*   **Current Price:** 776.44
*   **Last-market Info:** price = 795.935, previousClose = 776.44, change = 2.51
*   **5-day Moving Average:** 772.326
*   **20-day Moving Average:** 780.8965
*   **60-day Moving Average:** 777.4512

**Analysis:** The price is currently trading near its 60-day moving average. The price surge suggests recent positive momentum.  The 5-day moving average is below the 20-day, which could be a short-term bearish signal, but given the last-market price change of 2.51 and the current price of 795.935, there seems to be some sort of positive momentum.

### 3. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.3359 (Low Risk)
*   **RSI:** 50.18
*   **PPO:** -0.29
*   **Hybrid Signal:** Sell 69.7% of holdings (401 shares) - Caution - MRI:0.34
*   **Recent Relative Spread Change (20-day):** -1.7 (Decreasing)
*   **Expected Return (%):** 153.0

**Analysis:**

*   **MRI:** Indicates a low-risk environment for the stock.
*   **RSI:** Neutral (around 50), suggesting neither overbought nor oversold conditions.
*   **PPO:** Slightly negative, indicating a potential short-term downtrend.
*   **Hybrid Signal:** The hybrid signal is recommending to reduce LLY holdings due to market condition.
*   **Relative Spread Change:**  The decreasing spread suggests that LLY's recent outperformance relative to the S&P 500 is diminishing.
*   **Expected Return:**  A high expected return suggests that LLY is expected to significantly outperform the S&P 500 over the long term if purchased now.

### 4. Recent News & Significant Events

*   **2025-07-23:** Major business developments, regulatory changes, or market events.
*   **2025-07-24:** Analyst discussions of recent performance and outlook.
*   **2025-07-20:** Notable volatility.
*   **2025-07-22:** Market experts highlight risks and opportunities.

**Analysis:** Recent news indicates volatility, ongoing analysis, and significant events that could impact the stock.  Keep an eye on specific news releases to understand the nature of these events.

### 5. Recent Earnings Analysis

| 날짜       | EPS  | 매출        |
|------------|------|-------------|
| 2025-05-01 | 3.07 | 12.73 B$    |
| 2024-10-30 | 1.08 | 11.44 B$    |
| 2024-08-08 | 3.29 | 11.30 B$    |
| 2024-04-30 | 2.49 | 8.77 B$     |
| 2025-05-01 | 2.49 | 8.77 B$     |

**Analysis:**  The EPS and revenue figures show growth, although there's some variability.  Notably, the most recent data point (2025-05-01) shows a duplicated data point with both the highest revenue and the lowest revenue in the dataset. This needs clarification. If the $12.73B revenue corresponds to the $3.07 EPS for 2025-05-01, that represents a strong result.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-03-31 | $12.73B   | 82.53%        |
| 2024-12-31 | $13.53B   | 82.24%        |
| 2024-09-30 | $11.44B   | 81.02%        |
| 2024-06-30 | $11.30B   | 80.80%        |
| 2024-03-31 | $8.77B    | 80.91%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE       |
|------------|-----------|-----------|
| 2025-03-31 | $15.76B   | 17.50%    |
| 2024-12-31 | $14.19B   | 31.07%    |
| 2024-09-30 | $14.24B   | 6.81%     |
| 2024-06-30 | $13.56B   | 21.88%    |
| 2024-03-31 | $12.81B   | 17.51%    |

**Analysis:**

*   **Revenue and Profitability:** Revenue is generally increasing, and the profit margin is exceptionally high and stable, indicating strong pricing power and efficient operations.
*   **Capital and Profitability:** Equity is growing, and ROE is generally healthy.  The ROE fluctuation suggests some variability in profitability relative to equity.

### 7. Overall Assessment

Eli Lilly and Co. (LLY) demonstrates strong financial performance, with significant revenue and profit margin growth. It has vastly outperformed the S&P 500 over the long term.

**Key Points:**

*   **Strengths:** High growth potential, low market risk, strong financial metrics (revenue, profit margin, ROE), significant outperformance versus S&P 500.
*   **Weaknesses:** Relatively high maximum drawdown, decreasing relative spread, recent Hybrid Signal is to sell, and a short term possible downward trend.
*   **Considerations:** Monitor the news for specific events driving volatility and analyst outlook, and clarify the duplicated data from earnings and adjust accordingly.
*   **Investment Implication:** The data presents a mixed picture. The recent hybrid signal recommends reducing holdings, but the expected return is very high and market risk is low. The decision should be based on individual risk tolerance and investment horizon, the investor should consider all available data and make a decision based on their own unique circumstances.
